The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Impact of Vascular Endothelial Growth Factor-A Expression, Thrombospondin-2 Expression, and Microvessel Density on the Treatment Effect of Bevacizumab in Metastatic Colorectal Cancer
Open accessAbstract
Purpose: Bevacizumab is a monoclonal antibody to vascular endothelial growth factor-A (VEGF). In the pivotal trial in metastatic colorectal cancer (mCRC), addition of bevacizumab to first-line irinotecan, fluorouracil, and leucovorin (IFL) significantly prolonged median survival. The aim of these retrospective subset analyses was to evaluate VEGF, thrombospondin-2 (THBS-2), and microvessel density (MVD) as prognostic factors and/or predictors of benefit from bevacizumab. Patients and Methods: In the pivotal trial, 813 patients with untreated mCRC were randomly assigned to receive IFL plus bevacizumab or placebo. Of 312 tissue samples collected (285 primaries, 27 metastases), outcome data were available for 278 (153 bevacizumab, 125 placebo). Epithelial and stromal VEGF expression were assessed by in situ hybridization (ISH) and immunohistochemistry on tissue microarrays and whole sections. Stromal THBS-2 expression was examined by ISH on tissue microarrays. MVD was quantified by Chalkley count. Overall survival was associated with these variables in retrospective subset analyses. Results: In all subgroups, estimated hazard ratios (HRs) for risk of death were < 1 for bevacizumab-treated patients regardless of the level of VEGF or THBS-2 expression or MVD. Patients with a high THBS-2 score showed a nonsignificant improvement in survival following bevacizumab treatment (HR = 0.11; 95% CI, 0.02 to 0.51) compared to patients with a low score (HR = 0.65; 95% CI, 0.41 to 1.02); interaction analysis P = .22. VEGF or THBS-2 expression and MVD were not significant prognostic factors. Conclusion: These exploratory analyses suggest that in patients with mCRC addition of bevacizumab to IFL improves survival regardless of the level of VEGF or THBS-2 expression, or MVD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Self-citationThe Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Bärlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,099
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Self-citationGlobal cancer statistics in the year 2000
Parkin, D. M. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00486-7 · Cited by 2,445
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,608
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,370
Benjamin, L. E., Hemo, I., & Keshet, E. (1998) · Development · doi:10.1242/dev.125.9.1591 · Cited by 1,265
Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice
Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., & Hanahan, D. (1999) · Science · doi:10.1126/science.284.5415.808 · Cited by 988
Method for the Quantitative Morphologic Analysis of Tissues
(1943) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/4.1.47 · Cited by 961
Relf, M., LeJeune, S., Scott, P. A. E., Fox, S. B., Smith, K. A., Leek, R., Moghaddam, A., Whitehouse, R. M., Bicknell, R., & Harris, A. L. (1997) · PubMed · Cited by 833
Morgan, B., Thomas, A. L., Drevs, J., Hennig, J., Buchert, M., Jivan, A., Horsfield, M. A., Mross, K., Ball, H. A., Lee, L., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.092 · Cited by 652
Erber, R., Thurnher, A., D. Katsen, A., Groth, G., Kerger, H., Hammes, H., D. Menger, M., Ullrich, A., & Vajkoczy, P. (2004) · The FASEB Journal · doi:10.1096/fj.03-0271fje · Cited by 610
Identification of an angiogenic mitogen selective for endocrine gland endothelium
LeCouter, J., Kowalski, J., Foster, J., Hass, P., Zhang, Z., Dillard-Telm, L., Frantz, G., Rangell, L., DeGuzman, L., Keller, G.-A., et al. (2001) · Nature · doi:10.1038/35091000 · Cited by 555
Self-citationRodríguez-Manzaneque, J. C., Lane, T. F., Ortega, M. A., Hynes, R. O., Lawler, J., & Iruela-Arispe, M. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171460498 · Cited by 473
Fox, S. B., Leek, R. D., Weekes, M. P., Whitehouse, R. M., Gatter, K. C., & Harris, A. L. (1995) · The Journal of Pathology · doi:10.1002/path.1711770310 · Cited by 436
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
Bocci, G., Francia, G., Man, S., Lawler, J., & Kerbel, R. S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2135406100 · Cited by 414
Thrombospondins: Multifunctional Regulators of Cell Interactions
Adams, J. C. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.25 · Cited by 406
Takebayashi, Y., Akiyama, S.-I., Akiba, S., Yamada, K., Miyadera, K., Sumizawa, T., Yamada, Y., Murata, F., & Aikou, T. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.16.1110 · Cited by 363
Iruela-Arispe, M. L., Lombardo, M., Krutzsch, H. C., Lawler, J., & Roberts, D. D. (1999) · Circulation · doi:10.1161/01.cir.100.13.1423 · Cited by 308
Kim, K. J., Li, B., Houck, K., Winer, J., & Ferrara, N. (1992) · Growth Factors · doi:10.3109/08977199209023937 · Cited by 306
Thrombospondin-2: A potent endogenous inhibitor of tumor growth and angiogenesis
Streit, M., Riccardi, L., Velasco, P., Brown, L. F., Hawighorst, T., Bornstein, P., & Detmar, M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14888 · Cited by 302
Thrombospondin Type 1 Repeats Interact with Matrix Metalloproteinase 2
Bein, K., & Simons, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003834200 · Cited by 255
Gerber, H., Kowalski, J., Sherman, D. A., Eberhard, D. A., & Ferrara, N. (2000) · PubMed · Cited by 251
Bossi, P., Viale, G., Lee, A. K. C., Alfano, R. M., Coggi, G., & Bòsari, S. (1995) · PubMed · Cited by 243
Inhibition of Angiogenesis by Thrombospondin-2
Volpert, O. V., Tolsma, S. S., Pellerin, S., Feige, J. J., Chen, H., Mosher, D. F., & Bouck, N. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2780 · Cited by 201
Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer.
Kumar, H., Heer, K., Lee, P. W. R., Duthie, G. S., MacDonald, A. W., Greenman, J., Kerin, M. J., & Monson, J. R. T. (1998) · PubMed · Cited by 187
Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer
Hyodo, I., Doi, T., Endo, H., Hosokawa, Y., Nishikawa, Y., Tanimizu, M., Jinno, K., & Kotani, Y. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00282-2 · Cited by 175
Khorana, A. A., Ryan, C., Cox, C., Eberly, S. W., & Sahasrabudhe, D. M. (2003) · Cancer · doi:10.1002/cncr.11152 · Cited by 170
Kyriakides, T. R., Leach, K. J., Hoffman, A. S., Ratner, B. D., & BORNSTEIN, P. K. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4449 · Cited by 165
Jayson, G. C., Parker, G. J. M., Mullamitha, S., Valle, J. W., Saunders, M., Broughton, L., Lawrance, J., Carrington, B., Roberts, C., Issa, B., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.032 · Cited by 165
Jubb, A. M., Pham, T. Q., Hanby, A. M., Frantz, G. D., Peale, F. V., Wu, T. D., Koeppen, H. W., & Hillan, K. J. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.012963 · Cited by 163
Self-citationKuwai, T., Kitadai, Y., Tanaka, S., Onogawa, S., Matsutani, N., Kaio, E., Ito, M., & Chayama, K. (2003) · International Journal of Cancer · doi:10.1002/ijc.11068 · Cited by 162
and the Danish RANX05 Colorectal Cancer Study Group, Werther, K., Christensen, I. J., & Nielsen, H. J. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600075 · Cited by 123
Determination of Molecular Marker Expression Can Predict Clinical Outcome in Colon Carcinomas
Galizia, G., Lieto, E., Ferraraccio, F., Orditura, M., Vita, F. D., Castellano, P., Imperatore, V., Romano, C. P., Ciardiello, F., Agostini, B., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0960-03 · Cited by 115
DePrimo, S. E., Wong, L. M., Khatry, D., Nicholas, S. L., Manning, W. C., Smolich, B. D., O’Farrell, A.-M., & Cherrington, J. M. (2003) · BMC Cancer · doi:10.1186/1471-2407-3-3 · Cited by 100
Zheng, S. S. (2003) · World Journal of Gastroenterology · doi:10.3748/wjg.v9.i6.1227 · Cited by 100
Kuramochi, H., Hayashi, K., Uchida, K., Miyakura, S., Shimizu, D., Vallböhmer, D., Park, S.-J., Danenberg, K. D., Takasaki, K., & Danenberg, P. V. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1275 · Cited by 98
Kaio, E., Tanaka, S., Kitadai, Y., Sumii, M., Yoshihara, M., Haruma, K., & Chayama, K. (2002) · Oncology · doi:10.1159/000066511 · Cited by 92
Streit, M., Stephen, A. E., Hawighorst, T., Matsuda, K. M., Lange‐Asschenfeldt, B., Brown, L. F., Vacanti, J. P., & Detmar, M. J. (2002) · PubMed · Cited by 65
Prognostic value of plasma vascular endothelial growth factor in patients with colorectal cancer.
Nakayama, Y., 佐古, 達., Shibao, K., Okazaki, K., Rempo, N., Onitsuka, K., Minagawa, N., Akahane, K., Nagashima, N., Nagata, N., et al. (2002) · PubMed · Cited by 48
Morimoto, A. M., Tan, N., West, K. A., McArthur, G. A., Toner, G. C., Manning, W. C., Smolich, B. D., & Cherrington, J. M. (2004) · Oncogene · doi:10.1038/sj.onc.1207268 · Cited by 46
Lissoni, P., Rovelli, F., Malugani, F., Brivio, F., Fumagalli, L. A. M., & Gardani, G. (2003) · The International Journal of Biological Markers · doi:10.1177/172460080301800209 · Cited by 40
Jubb, A. M., Landon, T., Burwick, J. A., Pham, T. Q., Frantz, G. D., Cairns, B., Quirke, P., Peale, F. V., & Hillan, K. (2003) · The Journal of Pathology · doi:10.1002/path.1371 · Cited by 39
Self-citationSeki, N., Kodama, J., Hashimoto, I., Hongo, A., Yoshinouchi, M., & Kudo, T. (2001) · International Journal of Oncology · doi:10.3892/ijo.19.2.305 · Cited by 35
Thrombospondin-1 and -2 messenger RNA expression in epithelial ovarian tumor.
Kodama, J., Hashimoto, I., Seki, N., Hongo, A., Yoshinouchi, M., Okuda, H., & Kudo, T. (2001) · PubMed · Cited by 31
Cascinu, S., Graziano, F., Catalano, V., Staccioli, M. P., Barni, S., Giordani, P., Rossi, M. C., Baldelli, A. M., Muretto, P., Valenti, A., et al. (2000) · Clinical & Experimental Metastasis · doi:10.1023/a:1013133224044 · Cited by 30
Calabresi, P., Allegrini, G., Goulette, F. A., & Darnowski, J. W. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0712-y · Cited by 29
Konno, H., Abe, J., Kaneko, T., et al. (2001) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2001.tb01124.x · Cited by 29
An Optimized Protocol for In Situ Hybridization Using PCR-Generated 33P-Labeled Riboprobes
Lu, L. H., & Gillett, N. A. (1996) · Birkhäuser Boston eBooks · doi:10.1007/978-1-4612-4166-9_8 · Cited by 28
Frantz, G. D., Pham, T. Q., Peale, F. V., Jr., & Hillan, K. J. (2001) · The Journal of Pathology · Cited by 27
Self-citationCascinu, S., Graziano, F., Catalano, V., Barni, S., Giordani, P., Baldelli, A. M., Staccioli, M. P., Rossi, C., Brenna, A., Valenti, A., et al. (2003) · Tumor Biology · doi:10.1159/000071080 · Cited by 15
Cited by
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
Stem Cell–like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth Factor
Bao, S., Wu, Q., Sathornsumetee, S., Hao, Y., Li, Z., Hjelmeland, A. B., Shi, Q., McLendon, R. E., Bigner, D. D., & Rich, J. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1010 · Cited by 1,345
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,039
Metadata
- Authors
- Jubb, A. M., Hurwitz, H. I., Bai, W., Holmgren, E. B., Tobin, P., Guerrero, A. S., Kabbinavar, F., Holden, S. N., Novotny, W. F., Frantz, G. D., Hillan, K. J., & Koeppen, H.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-01-10
- Volume
- 24
- Issue
- 2
- Pages
- 217-227
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2157019123
- Cited by
- 387
- References
- 55
- FWCI
- 14.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.